South Korea · Delayed Price · Currency is KRW CellBion Statistics
Total Valuation
CellBion has a market cap or net worth of KRW 238.81 billion. The enterprise value is 213.08 billion.
| Market Cap | 238.81B |
| Enterprise Value | 213.08B |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CellBion has 12.82 million shares outstanding. The number of shares has increased by 22.71% in one year.
| Current Share Class | 12.82M |
| Shares Outstanding | 12.82M |
| Shares Change (YoY) | +22.71% |
| Shares Change (QoQ) | -24.13% |
| Owned by Insiders (%) | 36.45% |
| Owned by Institutions (%) | 3.59% |
| Float | 8.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 90.85 |
| PB Ratio | 9.05 |
| P/TBV Ratio | 9.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -28.68 |
| EV / Sales | 81.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -33.34 |
Financial Position
The company has a current ratio of 28.47, with a Debt / Equity ratio of 0.10.
| Current Ratio | 28.47 |
| Quick Ratio | 27.87 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.40 |
| Interest Coverage | -72.31 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -24.81% |
| Revenue Per Employee | 46.11M |
| Profits Per Employee | -130.36M |
| Employee Count | 57 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 25,176.20 |
| 200-Day Moving Average | 19,027.70 |
| Relative Strength Index (RSI) | 29.92 |
| Average Volume (20 Days) | 409,874 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CellBion had revenue of KRW 2.63 billion and -7.43 billion in losses. Loss per share was -665.27.
| Revenue | 2.63B |
| Gross Profit | 1.02B |
| Operating Income | -7.65B |
| Pretax Income | -7.43B |
| Net Income | -7.43B |
| EBITDA | -7.02B |
| EBIT | -7.65B |
| Loss Per Share | -665.27 |
Balance Sheet
The company has 28.29 billion in cash and 2.55 billion in debt, giving a net cash position of 25.73 billion or 2,007.55 per share.
| Cash & Cash Equivalents | 28.29B |
| Total Debt | 2.55B |
| Net Cash | 25.73B |
| Net Cash Per Share | 2,007.55 |
| Equity (Book Value) | 26.39B |
| Book Value Per Share | 2,058.87 |
| Working Capital | 28.53B |
Cash Flow
In the last 12 months, operating cash flow was -6.15 billion and capital expenditures -238.52 million, giving a free cash flow of -6.39 billion.
| Operating Cash Flow | -6.15B |
| Capital Expenditures | -238.52M |
| Free Cash Flow | -6.39B |
| FCF Per Share | -498.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | -290.98% |
| Pretax Margin | -282.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CellBion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.71% |
| Shareholder Yield | n/a |
| Earnings Yield | -3.11% |
| FCF Yield | -2.68% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |